VANCOUVER, BC--NovaDx International and its wholly-owned subsidiary Proteomix here entered into an agreement with German chemical and pharmaceutical company Bayer under which NovaDx will identify a series of osteoporosis genes. Bayer will pay up to $3 million to NovaDx based upon the successful completion of research milestones, and NovaDx will give Bayer access to a series of novel osteoclast-specific genes that may be potentially useful as drug targets for metabolic bone disease.